Active Ingredient History
Dextromethorphan is a non-narcotic morphine derivative widely used as an antitussive for almost 40 years. It has attracted attention due to its anticonvulsant and neuroprotective properties. It is a cough suppressant in many over-the-counter cold and cough medicines. In 2010, the FDA approved the combination product dextromethorphan/quinidine for the treatment of pseudobulbar affect. Dextromethorphan suppresses the cough reflex by a direct action on the cough center in the medulla of the brain. Dextromethorphan shows high-affinity binding to several regions of the brain, including the medullary cough center. This compound is an NMDA receptor antagonist and acts as a non-competitive channel blocker. It is one of the widely used antitussives and is used to study the involvement of glutamate receptors in neurotoxicity. Dextromethorphan (DM) is a sigma-1 receptor agonist and an uncompetitive NMDA receptor antagonist. The mechanism by which dextromethorphan exerts therapeutic effects in patients with pseudobulbar affect is unknown. Dextromethorphan should not be taken with monoamine oxidase inhibitors due to the potential for serotonin syndrome. Dextromethorphan is extensively metabolized by CYP2D6 to dextrorphan, which is rapidly glucuronidated and unable to cross the blood-brain barrier. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Combination drugs
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Abortion, Induced (Phase 3)
Adenoids (Phase 2)
Alzheimer Disease (Phase 4)
Amphetamine-Related Disorders (Phase 2/Phase 3)
Amyotrophic Lateral Sclerosis (Phase 3)
Analgesics, Opioid (Phase 1)
Anemia, Sickle Cell (Phase 4)
Anxiety (Phase 2)
Anxiety Disorders (Phase 2)
Atherosclerosis (Phase 4)
Autism Spectrum Disorder (Phase 2/Phase 3)
Autistic Disorder (Phase 2)
Bipolar Disorder (Phase 3)
Body Dysmorphic Disorders (Phase 2)
Brain Edema (Phase 2)
Brain Injuries, Traumatic (Phase 4)
Bronchitis (Phase 4)
Central Nervous System Stimulants (Phase 1/Phase 2)
Cigarette Smoking (Phase 2)
Cognition Disorders (Phase 1)
Colitis, Ulcerative (Phase 4)
Common Cold (Phase 4)
Cough (Phase 4)
Crohn Disease (Phase 4)
Crying (Phase 4)
Cytochrome P-450 CYP2D6 (Phase 4)
Cytomegalovirus Infections (Phase 1)
Dementia (Phase 4)
Depressive Disorder (Phase 1/Phase 2)
Depressive Disorder, Major (Phase 2)
Depressive Disorder, Treatment-Resistant (Phase 1/Phase 2)
Diabetes Mellitus, Type 2 (Phase 2)
Diabetic Neuropathies (Phase 2)
Drug Interactions (Phase 1)
Drug Therapy (Phase 2/Phase 3)
Dyskinesias (Phase 2)
Facial Neuralgia (Phase 2)
Fibromyalgia (Phase 2)
Food-Drug Interactions (Phase 1)
Graft Rejection (Phase 4)
Gulf War (Phase 2)
Healthy Volunteers (Phase 4)
Herpes Zoster (Phase 2)
HIV (Phase 1)
Huntington Disease (Phase 3)
Hyperalgesia (Phase 2)
Inflammation (Phase 4)
Intestinal Neoplasms (Phase 3)
Irritable Bowel Syndrome (Phase 2)
Irritable Mood (Phase 4)
Leukemia (Phase 3)
Leukemia, Myeloid, Acute (Phase 1)
Lymphoma (Phase 3)
Macular Edema (Phase 1/Phase 2)
Melanoma (Phase 1)
Migraine Disorders (Phase 2)
Mitochondrial Diseases (Phase 1)
Multiple Myeloma (Phase 3)
Multiple Sclerosis (Phase 3)
Multiple Sclerosis, Relapsing-Remitting (Phase 3)
Myelodysplastic Syndromes (Phase 3)
Myeloproliferative Disorders (Phase 3)
Neoplasms (Phase 3)
Neuralgia (Phase 2)
Neurodegenerative Diseases (Phase 2)
Obesity, Morbid (Phase 1/Phase 2)
Obsessive-Compulsive Disorder (Phase 2)
Opioid-Related Disorders (Phase 3)
Overweight (Phase 1/Phase 2)
Pain (Phase 3)
Pain, Postoperative (Phase 4)
Parkinson Disease (Phase 3)
Pharmacokinetics (Phase 1)
Porphyria, Acute Intermittent (Phase 1)
Porphyrias (Phase 1)
Precancerous Conditions (Phase 3)
Prostatic Neoplasms (Phase 1)
Proteinuria (Phase 3)
Pseudobulbar Palsy (Phase 4)
Psoriasis (Phase 1)
Psychomotor Agitation (Phase 3)
Respiratory Tract Infections (Phase 4)
Rett Syndrome (Phase 3)
Schizophrenia (Phase 2/Phase 3)
Signs and Symptoms (Phase 2)
Sinusitis (Phase 4)
Smoking (Phase 4)
Smoking Cessation (Phase 2)
Spinal Cord Injuries (Phase 4)
Stroke (Phase 4)
Substance-Related Disorders (Phase 2)
Tobacco Use Disorder (Phase 2)
Trigeminal Neuralgia (Phase 2)
Ultrasonography (Early Phase 1)
Voice Disorders (Phase 1)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
